Huizenga Theodore Alan sold $2K of RARE

Huizenga Theodore Alan (SVP, Chief Accounting Officer) sold 161 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $13.99 on 2026-09-03.

Original reporting
SEC EDGAR · Huizenga Theodore Alan
Published Sep 8, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 5:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
high confidence
Mentioned
$RARE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The sale is routine and unlikely to affect RARE's valuation, but it provides transparency on insider holdings.

02

Market read

Minor insider sale with negligible trading relevance; primarily of interest to compliance monitors.

03

What to watch

Potential upcoming earnings or pipeline news could outweigh this minor sale.

Relevance 3/10Novelty 4/10Timing: filing today

Background

Form 4 filings disclose insider transactions and are used to gauge insider sentiment.

Company-level read

Ticker impact

$RARENeutralHigh confidence
Context

Ultragenyx CFO Theodore Huizenga sold 161 shares at $13.99, reducing his stake to 69,146 shares.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The transaction size ($2.2k) is negligible relative to total float and insider holdings.

Market effects

No material effect on biotech sector.

Limited to US investors monitoring insider activity.

Insignificant for broader market.

Counterpoint

Some traders may view any insider sell as a red flag, but the tiny size suggests no real concern.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    Biotech firm developing treatments for rare diseases.

  • Theodore Huizenga

    Senior Vice President and Chief Accounting Officer at Ultragenyx.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.